What is Veozah?

Veozah (fezolinetant) is a nonhormonal prescription medicine approved in May 2023 to effectively reduce the frequency and severity of moderate to severe hot flashes caused by menopause.

This innovative medication offers a non-hormonal approach for managing one of the most common and disruptive symptoms of menopause. It represents a significant advancement for individuals seeking alternatives to traditional hormone therapies.

Key Characteristics of Veozah

Veozah is distinct in its mechanism of action and its purpose. Understanding its core features helps clarify its role in menopausal symptom management.

• Nonhormonal Treatment: Unlike hormone replacement therapies (HRT), Veozah does not contain hormones, making it a suitable option for those who cannot or prefer not to use hormonal treatments.
• Specific Indication: It is specifically approved to address vasomotor symptoms, commonly known as hot flashes, which can range from uncomfortable warmth to intense sweating episodes, significantly impacting daily life and sleep quality.
• Approval Date: Veozah received its approval in May 2023, making it a relatively new option available on the market for menopause-related hot flashes.

How Veozah Works: Its Drug Class

Veozah operates through a unique mechanism, classifying it into a specific group of medications.

• Neurokinin 3 (NK3) Receptor Antagonist: Veozah belongs to a drug class known as neurokinin 3 (NK3) receptor antagonists. This means it works by blocking the activity of the NK3 receptor, which plays a role in the brain's thermoregulatory center. By modulating this pathway, Veozah helps to reduce the occurrence and intensity of hot flashes.

Summary of Veozah

For a quick overview, here's a summary of Veozah's key details: